NOS

NOS
Name	Nitric oxide synthase
Ec number	1.14.13.39
Cofactors	Calmodulin, nicotinamide adenine dinucleotide phosphate
Substrates	L-arginine, O2, NADPH
Products	Nitric oxide, L-citrulline

NOS

Nitric oxide synthase is a family of heme-containing oxidoreductase enzymes that catalyze the production of nitric oxide and L-citrulline from L-arginine. First characterized in studies linking endothelium-dependent vasodilation to a diffusible factor, the enzyme family became central to research in cardiovascular physiology, neuroscience, and immunology. Work by investigators at institutions such as University of California, San Francisco, Harvard University, Max Planck Society, and University of Oxford expanded understanding of isoform-specific roles in health and disease.

Introduction

Nitric oxide synthase enzymes were identified following observations of endothelium-derived relaxing factor activity in preparations studied by teams at National Institutes of Health, University of Pennsylvania, and Columbia University. Early key papers connected NOS activity to signaling pathways investigated at Massachusetts Institute of Technology, Stanford University, and Karolinska Institutet. The NOS family bridged fields represented by societies such as the American Physiological Society and Society for Neuroscience, influencing research agendas at the World Health Organization and national funding bodies.

Nomenclature and Abbreviations

Standard nomenclature classifies NOS isoforms by tissue distribution and regulation: neuronal, endothelial, and inducible types. Commonly used abbreviations in the literature include nNOS, eNOS, and iNOS, terms established in consensus statements from groups at European Society of Cardiology and International Union of Biochemistry and Molecular Biology. Gene symbols for human isoforms appear in databases curated by National Center for Biotechnology Information and European Molecular Biology Laboratory. Historical synonyms appear in older reports from laboratories at Johns Hopkins University and University of Cambridge.

Types and Isoforms

Mammalian isoforms include neuronal NOS encoded by the gene examined in projects at Broad Institute and Wellcome Trust Sanger Institute, endothelial NOS studied extensively at Cleveland Clinic and Karolinska Institutet, and inducible NOS characterized in work from Imperial College London and Pasteur Institute. Alternative splice variants and orthologs are cataloged across species in resources maintained by Ensembl and UniProt Consortium. Comparative genomics efforts involving teams at Cold Spring Harbor Laboratory have traced NOS-related sequences in invertebrates, vertebrates, and microbial homologs described in research from Max Planck Institute for Molecular Genetics.

Biological Functions and Mechanisms

NOS-derived nitric oxide participates in vasodilation pathways uncovered in studies at Johns Hopkins Hospital and Mayo Clinic, neurotransmission mechanisms investigated by groups at Salk Institute and Rockefeller University, and host defense responses explored at Institut Pasteur and Walter Reed Army Institute of Research. Mechanistically, NOS enzymes use cofactors such as tetrahydrobiopterin and interact with regulatory proteins including caveolin-1, heat shock protein 90, and calmodulin, with signaling cross-talk described in reviews from American Heart Association symposia. Post-translational modifications affecting activity were delineated in collaborations involving University of Zurich and National University of Singapore.

Clinical Significance and Disorders

Dysregulation of NOS isoforms is implicated in pathologies studied at clinical centers like Cleveland Clinic, Mayo Clinic, and Johns Hopkins Hospital. Endothelial isoform dysfunction is associated with conditions evaluated in trials coordinated by European Society of Cardiology and American College of Cardiology, including hypertension and atherosclerosis. Neuronal isoform alterations relate to neurodegenerative and psychiatric disorders examined at Massachusetts General Hospital and Institute of Neurology, London. Inducible isoform overactivity features in inflammatory and infectious disease research led by Centers for Disease Control and Prevention and World Health Organization teams.

Pharmacology and Therapeutic Applications

Pharmacological modulation of NOS has been pursued by pharmaceutical groups at Pfizer, Novartis, and AstraZeneca as well as academic spin-offs from University of California, San Diego and Yale University. Drugs and investigational agents include nitric oxide donors referenced in trials by Food and Drug Administration and selective NOS inhibitors evaluated in oncology and sepsis studies at National Cancer Institute and European Medicines Agency. Therapeutic strategies leverage NOS modulation in organ transplantation research at Massachusetts General Hospital and pulmonary hypertension trials coordinated by Royal Brompton Hospital.

Research Methods and Measurement

Experimental approaches to study NOS employ molecular biology techniques refined at Cold Spring Harbor Laboratory, enzymatic assays standardized by labs at National Institute of Standards and Technology, and imaging modalities developed at University College London and Harvard Medical School. Common methods include gene knockout models from repositories at Jackson Laboratory, real-time detection of nitric oxide using electrodes and fluorescent probes pioneered at Rensselaer Polytechnic Institute and University of California, San Diego, and proteomic analyses facilitated by European Bioinformatics Institute. Cross-disciplinary consortia such as initiatives sponsored by Wellcome Trust and National Institutes of Health continue to advance methodology.

Category:Enzymes